NYSE · LLY
Eli Lilly and Company
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
Loading market information…
OTC · SONX · USD
Stock price, earnings
Quote as of Oct 28, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Sonendo, Inc.’s quoted price sits in the upper half of its reported 52-week range, 32.63% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Sonendo, Inc.’s next earnings report is currently expected on Nov 11, 2026, with estimated earnings per share of -$118.00. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Sonendo, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Sonendo, Inc. operates as a commercial-stage medical technology firm, dedicated to innovating, producing, and marketing advanced devices for root canal treatment across the United States and Canada. A flagship offering is GentleWave, an innovative device for addressing tooth decay that meticulously cleans and sanitizes the intricate microscopic passages within teeth without the need for removing any natural tooth structure. The company's product line also features SoundSeal, a specialized material used to construct and seal dental crowns, alongside its proprietary Sonendo-branded liquid solution of EDTA, which assists in the debridement and disinfection processes crucial for root canal systems. Furthermore, Sonendo provides "The Digital Office," a comprehensive practice management software solution designed to foster an integrated digital environment for dental professionals. Established in 2006, the organization was initially known as Dentatek Corporation before officially rebranding to Sonendo, Inc. in March 2011. Its corporate headquarters are situated in Laguna Hills, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:53 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2024 |
|---|
| May 8, 2024 |
| -$26.00-244.44% vs estimate |
| $7.05M+11.86% vs estimate |
| Q4 2023 | Mar 11, 2024 | -$24.00+20.0% vs estimate | $11.69M-0.92% vs estimate |
|---|
| Q3 2023 | Nov 8, 2023 | -$28.00-19,900.0% vs estimate | $10.41M+0.46% vs estimate |
|---|
THE ANALYST VIEW
5 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
$275.20+$4.16 (+1.53%)
Johnson & Johnson’s quoted price sits in the upper half of its reported 52-week range, 2.09% below the high.
$290.97+$4.98 (+1.74%)
AbbVie Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.55% below the high.
$9.57+$0.33 (+3.57%)
Sight Sciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 1.47% below the high.
$13.01+$0.08 (+0.62%)
NeuroPace, Inc.’s quoted price sits in the lower half of its reported 52-week range, 33.62% below the high.
$27.68+$0.40 (+1.47%)
Electromed, Inc.’s quoted price sits in the lower half of its reported 52-week range, 41.6% below the high.
$7.77-$0.24 (-3.0%)
Xilio Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 38.26% below the high.
$0.79-$0.01 (-1.38%)
Rapid Micro Biosystems, Inc.’s quoted price sits in the lower half of its reported 52-week range, 84.03% below the high.
